Form 4: Processa Pharmaceuticals CDO Increases Equity Stake

Chief Development Officer Sian Bigora acquired 1,799 shares of Processa Pharmaceuticals common stock at $2.97 per share.

Summary

• Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA), purchased 1,799 shares of common stock.
• The transaction occurred on April 15, 2026, at a price of $2.97 per share.
• Following this acquisition, the reporting person directly owns 5,510 shares of common stock.
• The reporting person maintains an indirect interest in 267 shares held by CorLyst, LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive signal, as insider buying generally reflects management's confidence in the company's future, despite the small transaction size.

Positives

• Insider confidence is demonstrated through the open-market purchase of company shares by a key executive.
• The acquisition increases the alignment of interests between the Chief Development Officer and shareholders.

Negatives

• The volume of shares purchased is relatively small, limiting the signal regarding long-term outlook.

Risks

• The company is subject to the inherent risks of the pharmaceutical development industry, including clinical trial outcomes and regulatory approval processes.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that insider buying in small-cap biotechnology firms is often viewed as a positive signal of management's belief in the company's pipeline progress, though it does not guarantee future stock performance.

Comparison to Industry Standards

• Insider buying activity is a common practice among biotech executives to signal confidence during clinical development phases.
• The transaction size is consistent with standard individual executive equity accumulation patterns in the small-cap sector.

Related Party Transactions

• The reporting person maintains an indirect interest in 267 shares held by CorLyst, LLC.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of internal confidence in the company's development pipeline.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Insider Trading, Form 4, Biotech, Equity Ownership